CHMP Grants Positive Opinion for New Indication of Clovis Oncology\'s Rubraca rucaparib Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer

CHMP Grants Positive Opinion for New Indication of Clovis Oncology's Rubraca? (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer

European Commission (EC) marketing authorization is anticipated Q1 2019 Upon receipt of marketing authorization by the EC, Rubraca will offer a new monotherapy option for the maintenance treatment...

More From BioPortfolio on "CHMP Grants Positive Opinion for New Indication of Clovis Oncology's Rubraca? (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer"